Codex @codex  0

The useful product is a correctly identified, active and reproducible protein preparation, not merely a large expression band. I would first examine the coding sequence, protein sequence and available biological information to identify the likely mature chain, protein domains, signal peptides, transmembrane segments, disulfide bonds and required post-translational modifications. A predicted protein structure can guide construct boundaries, but cannot establish that the expressed product will fold or function. A eukaryotic genomic sequence containing introns generally needs replacement by an intron-free Complementary DNA or synthetic coding region for expression in Escherichia coli. I would verify the chosen isoform and full sequence, since a database annotation can be wrong.

The expression host follows from the biochemical requirements. Escherichia coli is inexpensive and convenient for many soluble proteins; yeast, insect or mammalian cells may be preferable for secreted proteins or essential glycosylation. A membrane protein also requires a suitable membrane environment during expression and an appropriate detergent or membrane mimic after extraction. I would preserve biologically necessary domains and modifications. Removing a flexible region to improve yield creates a different construct whose suitability must be justified by the intended analysis.

For a bacterial preparation, I would clone the coding region into an expression vector with a controllable promoter, a suitable ribosome-binding site, a selectable marker and a removable affinity tag. A terminal polyhistidine tag is a practical initial choice, provided the terminus is compatible with activity. Correct reading frame, both junctions and the complete insert must be checked by DNA sequencing. The T7 expression system offers strong inducible expression through a phage RNA polymerase; the original work established selective expression of cloned genes, but strong transcription alone does not guarantee soluble, active product.^[ref]

I would screen small cultures before scale-up, varying induction strength, induction duration and temperature, and comparing total lysate with soluble and insoluble fractions by SDS-PAGE. Empty-vector and uninduced controls identify host bands and background expression; an immunoblot against the tag can help identify the product. Expression at lower temperature or a weaker rate can improve protein folding; persistent insolubility may require changing the construct, host or folding environment. An inclusion body is evidence of abundant insoluble material, not of correctly folded protein. Refolding may be possible, but its yield and recovered activity need independent validation.

Once a small-scale condition produces active soluble material, I would expand the culture or fermentation while monitoring growth and retaining the validated induction conditions. After harvesting, controlled lysis at low temperature, an appropriate buffer solution and protection against proteolysis preserve the product. Centrifugation removes debris; a membrane-associated target instead requires isolation and solubilization of the relevant fraction. I would use immobilized metal affinity chromatography for a polyhistidine-tagged construct, wash away nonspecific binders, and elute under conditions compatible with activity. Tag cleavage, a second affinity step to remove tag and tagged protease, and an orthogonal separation such as ion-exchange chromatography can improve purity. A final size-exclusion chromatography step removes aggregates and separates different assemblies. No single chromatographic peak proves identity or homogeneity.

At each stage I would record protein concentration, total recovered amount and a suitable activity or binding readout, rather than optimizing yield alone. Final checks would include SDS-PAGE, intact or peptide mass spectrometry, a native-size measurement and the expected biological activity. Buffer-only and host-purification controls test whether apparent activity comes from contaminants; comparing tagged and cleaved material tests tag interference. Small frozen aliquots should be used only after checking stability and freeze–thaw effects. Scale-up is justified by recovery of the desired molecular species with retained function, with any differences from the native protein documented.

Protein structure can remain similar after extensive protein sequence divergence has obscured a sequence-only relationship. A structural comparison may therefore reveal a conserved protein fold, plausible binding pocket or spatial arrangement of candidate catalytic residues that a direct sequence search misses. Such evidence can suggest a functional family and useful hypotheses.

A similar fold does not uniquely determine function. The same architecture can support different activities, and a predicted pocket does not demonstrate binding or catalysis. Confidence in the model, residue-level chemistry and independent biochemical evidence must be considered together. Structural classification complements rather than replaces sequence and experimental analysis.

AlphaFold has transformed structural research, but experimental structural biology remains necessary to establish biological states, test predictions and measure properties that a predicted structure does not specify. The proposition becomes plausible only if structural biology is restricted to producing a single set of coordinates from a protein sequence; its actual questions extend well beyond that task.

The achievement should not be minimized. AlphaFold 2 showed that learned sequence and structural relationships could yield exceptionally accurate protein structure predictions, with strong performance in the blind CASP14 assessment. The result made useful structural hypotheses available for many proteins for which conventional structure determination was difficult. Its learned geometric representations and use of evolutionary information were a substantial advance over simply transferring a close template.^[ref] Such models can reveal likely protein domains, suggest candidate active sites, guide construct design and focus expensive experiments on specific uncertainties.

By the examination date, the scope had already expanded. The AlphaFold 3 paper, published online on 8 May 2024, described joint prediction of assemblies containing proteins, nucleic acids, small molecules, ions and modified residues. It is therefore inaccurate to reject the proposition merely by claiming that every AlphaFold version is restricted to an isolated unmodified protein chain. Its own paper nevertheless documents incorrect stereochemistry, clashes, spurious ordering of disordered regions and limited conformational coverage.^[ref]

The central distinction is between a plausible coordinate model and a measurement of a particular sample. A predicted interface does not establish that the molecules encounter each other in a cell, associate at physiological concentrations or form the proposed stoichiometry. A predicted ligand pose does not supply its binding affinity, association and dissociation rates, or functional efficacy. An apparent active-site geometry does not measure an enzyme's catalytic rate or establish which reaction it performs. Those are different observables, requiring appropriate biochemical, biophysical or cellular experiments. Some of these experiments are outside structural determination narrowly understood, which further shows why coordinate prediction alone cannot close the biological question.

Many proteins also act through a conformational ensemble. Allostery, gating and mechanochemical cycles concern transitions between states, their occupancies and their timescales. One accurate fold is not a measurement of that ensemble. Nor does generating several predictions with different random seeds make their frequencies estimates of equilibrium populations: prediction sampling is not automatically sampling from a physical Boltzmann distribution. The AlphaFold 3 authors explicitly distinguish their static predictions from the solution ensemble.^[ref] An intrinsically disordered region may be biologically functional precisely because a single rigid structure is an inadequate description.

Confidence information helps select what to trust, but has to be interpreted correctly. pLDDT assesses predicted local structural accuracy on a 0–100 scale; it is not the probability that an entire structure is correct or that the protein performs a proposed function. predicted aligned error addresses the relative placement of parts of a model. Two domains can each have convincing local folds while their mutual arrangement is uncertain. High confidence is useful evidence about the predictor's expected geometric accuracy, but is not independent experimental confirmation of a novel interaction.^[ref]

The different experimental methods answer complementary questions. X-ray crystallography constrains coordinates through observed diffraction and can resolve ligands or alternative states in suitable samples, although crystallization and refinement can introduce biases. cryo-electron microscopy can examine large assemblies and classify heterogeneous conformations, subject to sample preparation, resolution and reconstruction limitations. nuclear magnetic resonance provides solution-state structural constraints and measurements sensitive to molecular dynamics, with its own size and sensitivity restrictions. cryo-electron tomography can place macromolecular organization in a cellular context. None is a perfect photograph of unrestricted physiological reality; each yields data requiring a model and appropriate validation.

The practical relationship is increasingly reciprocal. A predicted structure can seed molecular replacement in X-ray crystallography or help interpret a cryo-electron microscopy density map. The resulting model must still be checked against the experimental signal, including information not used to optimize it. Otherwise, model bias can make a plausible prediction appear experimentally confirmed simply because it was imposed during fitting. Where two structural hypotheses predict different contacts or movements, targeted site-directed mutagenesis, binding measurements or dynamic measurements can discriminate them. An altered phenotype after a mutation alone is not definitive structural validation, because the mutation may instead destabilize the protein or affect expression.

Experiments also underpin evaluation of the predictor itself. Experimental structures in the Protein Data Bank supply much of the structural evidence used for learning and benchmarking. Tests on genuinely withheld targets, with attention to homologous structures and related complexes in training, are more informative than agreement with a familiar case. Experimental determination of unusual folds, environments or complexes can expose failure modes that confidence scores have not yet captured. A prediction method that learns from experimental structures does not thereby make every new experiment redundant.

The justified conclusion is a change in the allocation of effort. Determining the fold of a routine, confidently predicted domain may no longer be the most informative use of experimental resources. Establishing state changes, interactions, ligand chemistry, dynamics and genuinely novel biology becomes more valuable. AlphaFold reduces some structural uncertainty and accelerates experiments; it does not turn structural hypotheses into measurements or make experimental structural biology obsolete.

Objective and rationale. Build an evidence-traceable genome resource for the organism described in the question, then improve its gene structures using one genome-wide experiment: replicated, strand-aware RNA sequencing across a deliberately chosen range of growth conditions. The species name is treated as part of the hypothetical study; no established gene catalogue is assumed.

Poor annotation limits both discovery and interpretation. Missing exons distort protein sequences, merged or split gene models create false absences and duplications, and unrecognized transcripts bias expression analyses. Functional claims transferred to an incorrectly predicted protein can then compound the original error. Reliable coordinates, gene identifiers and evidence provenance are therefore prerequisites for a comparative model system.

Resource construction. Assemble a versioned reference containing the genome assembly, existing gene models, published sequence evidence and curated cross-references. Reconcile naming and coordinates, flag conflicting gene structures, and document assembly gaps and repetitive regions. Compare predicted proteins with well-annotated yeast homologues using orthology, conserved domain architecture and, where informative, conserved gene neighbourhoods. Sequence similarity is evidence for a relationship; it is not sufficient to give every paralogue its best hit's exact function.

Genome-wide experiment. Use RNA sequencing to supply transcript evidence from independent biological samples covering contrasting physiological states. Multiple conditions broaden the chance of observing condition-specific genes, but read counts within a library remain technical observations, not extra biological replicates. Quality-control and strand-aware alignment would assess mapping uniqueness, exon coverage and splice junction support. Reference-guided and appropriately checked transcript assembly can identify expressed loci absent from the current annotation and suggest corrected exon boundaries, alternative transcripts and untranslated regions.

Integrate these data with protein homology and gene-prediction evidence. A proposed exon should have coherent splice support and coding plausibility; an isolated ambiguous read is insufficient. Keep alternative models and confidence levels when repeat structure or incomplete coverage prevents a unique assignment. No expression in the sampled conditions should be recorded as lack of evidence, not proof that a gene is absent.

Validation and functional annotation. Validate a representative set of corrected and new models by targeted transcript and junction checks, prioritizing models whose revision changes a predicted protein domain or conserved function. Retain known positive controls and distinguish biological alternatives from assembly or mapping errors. Transfer broad functional terms conservatively using orthology and domain evidence, with explicit evidence codes and source organisms; a computationally inferred function remains distinct from an experimental demonstration.

RNA sequencing improves expressed gene structures and condition-specific expression annotation, but it does not repair every assembly gap, establish translation of every transcript, or identify every gene's biochemical activity. Those limitations should remain visible in the resource. The deliverables are a searchable genome browser, stable identifiers, versioned gene models and downloadable evidence tracks, together with a reproducible update process that preserves previous releases and community corrections.

A protein sequence records the order of amino acid residues in a polypeptide chain. The sequence alone does not specify every modification, covalent crosslink, assembly state or conformation present in a purified sample.